On July 1, Xiao Lihui, Secretary of the Party Committee of Shenzhen Hospital of Southern Medical University, Wu Dinglan, deputy director of Clinical Medicine Innovation Center, Cao Xuhui, Vice president of Shenzhen Yudong Packaging Technology Co., LTD., Wang Jiannan, chairman of Shenzhen Faith Investment Management Co., LTD., and Liu Shiyang, Investment Director, visited Shenzhen Cell Valley for exchange and visit. Our chairman Professor Shi Yuanyuan, chief medical consultant Dr. David Kin Jin, Marketing Minister Sun Rui, General Office director Luan Zhishi, senior research and development scientist Fu Yuchen warmly received, and discussed the clinical research and progress of cell therapy products.

Under the leadership of Professor Shi Yuanyuan, Secretary Xiao and his party visited the smart exhibition hall and digital monitoring system, and made a preliminary understanding of the development history of Shenzhen Cell Valley, the core team, and the production, research and development, quality management and industrialization talent training bases in Shenzhen and Zhongshan.

At the symposium, Professor Shi Yuanyuan introduced in detail the current situation of cell therapy at home and abroad, the strategic layout of our company and the core technology. Professor Shi Yuanyuan said that Shenzhen Cell Valley South China Cell Factory project is a municipal major project approved by Shenzhen Municipal Development and Reform Commission, and is also a major public service platform for Shenzhen biomedicine industry, cooperating with many top three hospitals to jointly promote clinical research and application development of cell therapy. Cell therapy has made remarkable achievements in improving patient survival and reducing the burden of cancer. Using the domestic leading retroviral vector GMP industrial production process, our company has provided high-quality and safe customized target CAR cell preparation services for many well-known medical institutions at home and abroad. Dozens of patients with recurrent or drug-resistant blood tumors who did not respond to previous treatment experienced significant remission after treatment with CAR T cells prepared by the Cell Valley team. At the same time, the NK and CAR-NK cell therapy products recently launched by Cell Valley have been widely used in clinical studies of solid tumors such as liver cancer and pancreatic cancer and autoimmune diseases. Shenzhen Cell Valley has always adhered to the mission values of "cells benefit all beings and genes create the future", and is committed to solving the key constraints such as technology, cost, production capacity and talent in cell therapy drugs/clinical treatment, and opening up more treatment ways for patients.

Xiao Lihui, secretary of Shenzhen Hospital of Southern Medical University, said that cell therapy is becoming a new focus of the development of the medical and health industry, and the future cell clinical treatment model will be full cycle and all-round, and its popularization and promotion cannot be achieved without the unremitting technological development of scientific research teams and the application and transformation of high-level clinical treatment teams. The Clinical Medicine Innovation Center of Shenzhen Hospital of Southern Medical University is a comprehensive platform integrating basic medicine, clinical transformation and precision medicine approved by Shenzhen Development and Reform Commission, which can carry out scientific research around clinical problems and explore more innovative and effective treatment methods for patients.

Both parties said that they will give full play to their respective technical resources, core teams and platform advantages, and jointly contribute to promoting the clinical application of cell therapy.